Meningococcal polysaccharide A O-acetylation levels do not impact the immunogenicity of the quadrivalent meningococcal tetanus toxoid conjugate vaccine: results from a randomized, controlled phase III study of healthy adults aged 18 to 25 years.
about
Meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine: a new conjugate vaccine against invasive meningococcal diseaseFactors contributing to the immunogenicity of meningococcal conjugate vaccinesRoutinely vaccinating adolescents against meningococcus: targeting transmission & diseaseMeningococcal quadrivalent tetanus toxoid conjugate vaccine (MenACWY-TT, Nimenrix™): A review of its immunogenicity, safety, co-administration, and antibody persistence.
P2860
Meningococcal polysaccharide A O-acetylation levels do not impact the immunogenicity of the quadrivalent meningococcal tetanus toxoid conjugate vaccine: results from a randomized, controlled phase III study of healthy adults aged 18 to 25 years.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 24 July 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Meningococcal polysaccharide A ...... hy adults aged 18 to 25 years.
@en
Meningococcal polysaccharide A ...... hy adults aged 18 to 25 years.
@nl
type
label
Meningococcal polysaccharide A ...... hy adults aged 18 to 25 years.
@en
Meningococcal polysaccharide A ...... hy adults aged 18 to 25 years.
@nl
prefLabel
Meningococcal polysaccharide A ...... hy adults aged 18 to 25 years.
@en
Meningococcal polysaccharide A ...... hy adults aged 18 to 25 years.
@nl
P2093
P2860
P356
P1476
Meningococcal polysaccharide A ...... hy adults aged 18 to 25 years.
@en
P2093
Jacqueline M Miller
Kriengsak Limkittikul
Marie Van der Wielen
Nestor Sosa
Pornthep Chanthavanich
Socorro Lupisan
Véronique Bianco
Yaela Baine
P2860
P304
P356
10.1128/CVI.00162-13
P577
2013-07-24T00:00:00Z